These findings imply the major role of PI3K/AKT/mTOR signaling in SDC and EMC tumorigenesis and offer the opportunity for an individualized cancer therapy targeting PI3K/AKT/mTOR pathway effectors. Here, AKT1 is linked to extraskeletal myxoid chondrosarcoma.